Taxotere Epiphora Lawsuit Filed Over Excessively Watery Eyes
Sanofi now faces nearly 170 Taxotere epiphora lawsuits from breast cancer patients who say they were left with excessive tearing and watery eyes after the chemotherapy treatments.
Tag Archives: Sanofi-Aventis
-
-
Lack of Taxotere Warnings Over Blocked Tear Ducts Justify Lawsuits Moving Forward
Plaintiffs in Taxotere eye injury litigation say their lawsuits are justified in moving forward because Sanofi failed to put adequate tear duct injury warnings on the label.
-
Motion Filed to Dismiss Taxotere Lawsuits Over Excessive Tearing Problems
Sanofi has filed a motion to dismiss Taxotere excessive tearing lawsuits on the basis of a label warning critics have said is inadequate.
-
Taxotere Lawsuit Filed Over Tear Duct Obstruction That Required Painful Eye Surgery
A Taxotere lawsuit filed by a Virginia woman claims she suffered tear duct obstruction and required painful surgery after using Taxotere for only two months.
-
Appeals Court Overturns Defense Verdict from First Taxotere Hair Loss Bellwether Trial
A federal appeals court has overturned a defense verdict in the first Taxotere hair loss bellwether trial, calling for a new trial to be held.
-
Lawsuits Over Taxotere Eye Side Effects Consolidated In Louisiana Federal Court
Taxotere eye injury lawsuits filed in federal courts nationwide will be consolidated and centralized in the U.S. District Court for the Eastern District of Louisiana for pretrial proceedings.
-
Taxotere Eye Injury Lawsuits To Be Considered for MDL Consolidation
A panel of judges has agreed to consider consolidating all Taxotere eye injury lawsuits filed in federal courts before one judge as part of a second multidistrict litigation involving the…
-
Taxotere Eye Problems Result In Lawsuits Against Sanofi Over Failure to Warn About Breast Cancer Drug Risks
Sanofi faces several new lawsuits claiming Taxotere eye problems resulted in vision damage and vision loss, which may be folded together into a new MDL for the breast cancer drug.
-
Sanofi Cleared of Liability in Bellwether Lawsuit Over Permanent Chemotherapy Hair Loss from Taxotere
A second Taxotere bellwether trial over permanent hair loss has resulted in a defense verdict.
-
Recalled Zantac OTC Brand Return To Market With Generic Pepcid Ingredient
This week, Sanofi announced intentions to re-launch Zantac under the name Zantac 360, which will use the active ingredient from Pepcid instead of ranitidine, which has been linked to increased…
